A Two-year Study of Telbivudine in HBeAg Negative Hepatitis
Status:
Completed
Trial end date:
2014-05-30
Target enrollment:
Participant gender:
Summary
Based on GLOBE study supplying predictability analysis results, ROADMAP strategy provides an
individualized telbivudine treatment roadmap strategy designed to achieve optimal viral
suppression and low resistance rate in patients with chronic hepatitis B(CHB), which includes
adding ADV treatment at different time points according to individual patient response. China
CHB Guidelines (China Medical Association 2010) make impress on and confirm LDT ROADMAP
strategy particularly, which may be a large potential to expand the naïve patients. We are
lack of optimal model in HBeAg(-). In China HBeAg(-) is around 38% of total CHB patients. In
GLOBE study, LdT treatment against HBeAg(-) patients with HBV DNA <7log showed a good 2 year
efficacy, but we still look forward to more efficient treatment and lower resistance rate.
This study complies with the principle of individualized therapy recommended and ethical
principles. It is expected that this study design with individualized treatment approach may
improve efficacy and lower the resistance rates. In addition, it will provide important
information on how to bring greater benefits to patients with CHB.